Reductions in Infections and Associated Complications in Nine Common Variable Immunodeficiency Patients Treated with Immune globulin intravenous, human-slra
Common variable immunodeficiency (CVID) is a primary immune deficiency disease characterized by defects in humoral immunity. Individuals with CVID often experience frequent bacterial and viral infections of the upper airway, sinuses, and lungs despite standard immunoglobulin replacement therapy (IgRT). IgRT’s are subject to requirements established in 21 CFR 640 that define minimum concentrations for antibodies against only measles, diphtheria, and polio1. There is no standardization of IgG titers against common, problematic respiratory pathogens.
Immune globulin intravenous (IVIG), human-slra 10% (ASCENIVTM) is a unique IgRT that meets all CFR640 criteria and is manufactured from blending normal source plasma with plasma from donors that possess high antibody titers against RSV2 and other common circulating respiratory viruses including influenza A and B, parainfluenza serotypes 1, 2, and 3, human metapneumovirus, and seasonal coronaviruses 229E and OC433.